Novartis AG (NYSE: NVS) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
140.37
-0.55-0.39%
TA
Loading chart...
Snapshot
| Index | - | P/E | 21.24 | EPS (ttm) | 6.61 | Insider Own | - | Shs Outstand | 1.90B | Perf Week | 2.34% |
| Market Cap | 266.00B | Forward P/E | 14.33 | EPS next Y | 9.79 | Insider Trans | - | Shs Float | 1.83B | Perf Month | -12.44% |
| Enterprise Value | 307.51B | PEG | - | EPS next Q | 2.24 | Inst Own | 7.54% | Short Float | 0.31% | Perf Quarter | -4.56% |
| Income | 12.64B | P/S | 4.86 | EPS this Y | 32.66% | Inst Trans | - | Short Ratio | 3.04 | Perf Half Y | -5.28% |
| Sales | 54.79B | P/B | 6.40 | EPS next Y | 11.36% | ROA | 10.34% | Short Interest | 5.63M | Perf YTD | 1.81% |
| Book/sh | - | P/C | 14.74 | EPS next 5Y | 9.33% | ROE | 29.64% | 52W High | 170.46 -17.65% | Perf Year | 14.62% |
| Cash/sh | - | P/FCF | 16.65 | EPS past 3/5Y | 31.39% 15.36% | ROIC | 13.38% | 52W Low | 121.57 15.46% | Perf 3Y | 47.18% |
| Dividend Est. | 4.74 (3.38%) | EV/EBITDA | 13.95 | Sales past 3/5Y | 8.04% 1.90% | Gross Margin | 74.29% | Volatility | 1.49% 1.52% | Perf 5Y | 73.64% |
| Dividend TTM | 4.74 (3.38%) | EV/Sales | 5.61 | EPS Y/Y TTM | 12.95% | Oper. Margin | 29.86% | ATR (14) | 3.77 | Perf 10Y | 109.07% |
| Dividend Ex-Date | Mar 11, 2026 | Quick Ratio | 0.67 | Sales Y/Y TTM | 7.57% | Profit Margin | 23.09% | RSI (14) | 37.77 | Recom | 2.84 |
| Dividend Gr. 3/5Y | 6.30% 5.28% | Current Ratio | 0.86 | EPS Q/Q | -0.41% | SMA20 | -6.08% | Beta | 0.42 | Target Price | 153.00 |
| Payout | 67.77% | Debt/Eq | 1.18 | Sales Q/Q | -2.82% | SMA50 | -7.92% | Rel Volume | 1.07 | Prev Close | 140.92 |
| Employees | 75,267 | LT Debt/Eq | 0.67 | Earnings | Oct 27 | SMA200 | -6.54% | Avg Volume | 2.10M | Price | 140.37 |
| IPO Date | Nov 07, 1996 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.95% 2.43% | Net Debt/EBITDA | 1.88 | Volume | 2,231,847 | Change | -0.39% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-10-26 | Upgrade | HSBC | Reduce → Hold | $112 → $136 |
| Mar-26-26 | Reiterated | Morgan Stanley | Overweight | $143 → $170 |
| Jan-06-26 | Upgrade | Barclays | Underweight → Equal Weight | |
| Dec-10-25 | Reiterated | HSBC | Hold | $106 → $112 |
| Dec-08-25 | Upgrade | JP Morgan | Neutral → Overweight | |
| Dec-03-25 | Reiterated | Morgan Stanley | Equal Weight | $136 → $143 |
| Oct-29-25 | Reiterated | CFRA | $108 → $126 | |
| Sep-12-25 | Downgrade | Goldman Sachs | Neutral → Sell | |
| Feb-13-25 | Downgrade | UBS | Buy → Neutral | |
| Nov-19-24 | Downgrade | Erste Group | Buy → Hold |
Latest News· Times ET
Sep-16-26
Sep-15-26
Sep-15-2602:44PM
07:15AM
04:46AM
Sep-14-26
Sep-14-2612:44AM
Sep-11-26
10:54AM
Sep-10-26
03:36AM
Sep-09-26
Company
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Ownership
Total institutional ownership7.54%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 55,635 | 54,811 | 51,722 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 14,221 | 13,690 | 12,827 | — | — | — | — | — | — | |
| Gross Profit | 41,414 | 41,122 | 38,895 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 13,127 | 13,306 | 12,566 | — | — | — | — | — | — | |
| Research and Development | 11,280 | 10,742 | 10,022 | — | — | — | — | — | — | |
| Other Operating Expense | 16 | 0 | 1,763 | — | — | — | — | — | — | |
| Operating Income | 16,992 | 17,074 | 14,544 | — | — | — | — | — | — | |
| Interest Expense | 1,390 | 1,187 | 1,036 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -77 | 549 | 132 | — | — | — | — | — | — | |
| Net Income Before Taxes | 15,525 | 16,436 | 13,640 | — | — | — | — | — | — | |
| Income Taxes | 2,776 | 2,397 | 1,701 | — | — | — | — | — | — | |
| Consolidated Net Income | 12,759 | 14,056 | 11,941 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 12,749 | 14,039 | 11,939 | — | — | — | — | — | — | |
| Net Income | 12,759 | 14,056 | 11,941 | — | — | — | — | — | — | |
| EPS (Recurring) | 6.66 | 7.25 | 5.92 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 6.66 | 7.25 | 5.92 | — | — | — | — | — | — | |
| EPS (Diluted) | 6.63 | 7.19 | 5.87 | — | — | — | — | — | — | |
| EBITDA | 22,260 | 22,987 | 20,715 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 21.17 | 19.18 | 16.58 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.81 | 4.88 | 3.80 | — | — | — | — | — | — | |
| Gross Margin | 74.44 | 75.03 | 75.20 | — | — | — | — | — | — | |
| Operating Margin | 30.54 | 31.15 | 28.12 | — | — | — | — | — | — | |
| Net Margin | 22.93 | 25.64 | 23.09 | — | — | — | — | — | — | |
| Shares Outstanding | 1,905 | 1,939 | 2,018 | — | — | — | — | — | — | |
| Market Capitalization | 267,405 | 267,330 | 196,372 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.